$46.53
1.21% today
Nasdaq, Sep 25, 05:48 pm CET

Supernus Pharmaceuticals, Inc. Stock price

$47.10
+2.67 6.01% 1M
+14.40 44.04% 6M
+10.94 30.25% YTD
+16.53 54.07% 1Y
+14.56 44.74% 3Y
+26.90 133.17% 5Y
+28.89 158.65% 10Y
+41.73 777.10% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
+0.27 0.58%

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.1b
Net debt
positive
Cash
$522.6m
Shares outstanding
56.1m
Valuation (TTM | estimate)
P/E
41.3 | 20.8
P/S
4.0 | 3.8
EV/Sales
3.2 | 3.0
EV/FCF
11.4
P/B
2.5
Financial Health
Equity Ratio
75.7%
Return on Equity
7.1%
ROCE
5.9%
ROIC
6.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$665.1m | $703.4m
EBITDA
$142.5m | $122.4m
EBIT
$64.1m | $126.1m
Net Income
$64.5m | $127.3m
Free Cash Flow
$185.9m
Growth (TTM | estimate)
Revenue
5.6% | 6.3%
EBITDA
30.7% | -27.4%
EBIT
141.8% | 39.2%
Net Income
1,135.6% | 72.3%
Free Cash Flow
20.4%
Margin (TTM | estimate)
Gross
89.9%
EBITDA
21.4% | 17.4%
EBIT
9.6%
Net
9.7% | 18.1%
Free Cash Flow
27.9%
More
EPS
$1.1
FCF per Share
$3.3
Short interest
12.2%
Employees
674
Rev per Employee
$980.0k
Show more

Is Supernus Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Supernus Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Supernus Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
665 665
6% 6%
100%
- Direct Costs 67 67
8% 8%
10%
598 598
7% 7%
90%
- Selling and Administrative Expenses 333 333
1% 1%
50%
- Research and Development Expense 107 107
10% 10%
16%
142 142
31% 31%
21%
- Depreciation and Amortization 78 78
5% 5%
12%
EBIT (Operating Income) EBIT 64 64
142% 142%
10%
Net Profit 65 65
1,136% 1,136%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Supernus Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Supernus Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
8 days ago
Supernus Pharmaceuticals shares have rallied nicely after strong 2Q25 results, driven by robust Qelbree and Gocovri sales and a surge in Zurzuvae revenue. Supernus' recent acquisition of Sage Therapeutics added Zurzuvae, the only FDA-approved oral postpartum depression drug, and bolstered the company's balance sheet. Management raised FY25 revenue guidance by 11% and expects continued growth, w...
Neutral
GlobeNewsWire
29 days ago
ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today management will participate in the following September investor conferences: Cantor Global Healthcare Conference Date:Fireside chat:Place:     We...
Neutral
Seeking Alpha
about 2 months ago
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jack A. Khattar - Founder, President, CEO, Secretary & Director Timothy C.
More Supernus Pharmaceuticals, Inc. News

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Head office United States
CEO Jack Khattar
Employees 674
Founded 2005
Website www.supernus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today